Table 1

Characteristics of the analysed cohorts with primary Sjögren’s syndrome (pSS) and healthy controls

Discovery cohort 1Replication cohort 2
Patients with pSS (n=17)Controls (n=15)Patients with pSS (n=27)Controls (n=12)
Age, mean±SD years56.4±1660.8±16.564.2±13.465.6±16.9
Female sex (%)100100100100
Negative anti-SSA and anti-SSB (%)7 (41.2%)1006 (22.2%)100
Positive anti-SSA (%)10 (58.8%)21 (77.8%)
Positive anti-SSA and anti-SSB (%)5 (29.4%)14 (51.9%)
ESSDAI, mean±SD (range)3.8±8.2 (0–19)6.4±7.2 (0–29)
Treatments
Methotrexate (15 mg/week) (%)2 (11.7%)3 (11.1%)
Hydroxychloroquine (400 mg/day) (%)5 (29.4%)9 (33.3%)
  • ESSDAI, EULAR Sjögren’s Syndrome Disease Activity Index.